Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform and its pipeline includes five differentiated, first-in-class oral peptide programs, expected to enter the into the clinic (Phase 1 to Phase 3) by 2025. The Company’s most advanced product candidate, EB613 (oral PTH (1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s ruling of a quantitative BMD endpoint which is expected to occur by January 2025. The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.

TRIGR was a stealth, private clinical stage, bispecific antibody company, acquired by Compass Therapeutics (Nasdaq: CMPX) in June 2021. Served as point person for strategic/BD negotiation; sin-licensed therapeutic portfolio from ABL Bio; negotiated and executed $117 million Elpiscience China License for CPX-009; oversee and manage day to day R&D/ clinical strategy

Served as head of healthcare investment banking at FBR following its acquisition of MLV & Co in September 2015. Devised efficient financings of micro-cap and mid-market biotech and spec pharma companies across the capital structure (equity, debt, royalty securitization, structured). Since 2012, completed over 100 IPO, ATM and follow on equity offerings totaling over $4 billion in aggregate value. https://www.fbr.com/services/investment-banking/transactions/

Specialized in transactions where value dislocations in equity markets created opportunities to acquire valuable therapeutic royalty assets from publicly traded biopharmaceutical companies. Focus on oncology/hematology, auto-immune / infectious disorders, mostly biological acquisitions (mAbs and other targeted therapies)Main responsibilites included (1)Origination and fundamental analysis of clinically differentiated, long duration biopharmaceutical assets in anticipation of key inflection points, (2) Extensive clinical, commercial, IP and financial diligence of therapeutic assets and stocks, (3) Construction of bottoms-up therapeutic models with sales sensitivity scenarios (event, duration, IP), (4) Devising proprietary estimates and valuation of product economics and company securities vs. Wall St. consensus. Select (disclosed) transactions: Atripla/Truvada/Emtriva ($525 million), Humira ($700 million), Remicade ($650 million); oncology focused antibody assets via securitization transactions

Founded a new profit center reporting directly to CEO, Itzhak Forer; advised over 100 early stage private biotech and medical device clients over 4.5 years (Protalix, Novocure, Quark Biotech, Clal Biotechnology, Danziger, Compugen)